BioSpace News Archive

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2020 , during w

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced five presentations featuring the company’s endocrinology rare disease programs at two upcoming medical conferences: European Calcified Tissue Society (ECTS) 2020, taking place online October 22–24, 2020, and the Pediatric Endocrinology Nursing Society (PENS) national conference,

Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the TIGIT Therapies Digital Summit 2020 being held virtually October 26 – 27, 2020. Presentation Details Presentation Title: Us

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders announces the publication on October 14, 2020 in the Journal of the American Academy of Child & Adolescent Psychiatry

The spot vision screener refers to a portable, handheld gadget that is designed to assist users easily and quickly to detect issues pertaining to sight on patients aged from 6 months to adulthood.

Increased instances of medical errors together with growing inclination among healthcare providers toward offering superior patient safety and care services is foreseen to help in the swift expansion of the global patient safety and risk management software market during 2019–2029.

The prevailing unhealthy food habits and hectic lifestyle of consumers across the world are the primary drivers of the global migraine drugs market.

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 per share.

Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. announced that the company is collaborating with Amazon Web Services, Inc. and Onica, a Rackspace Technology company, to build and host its Digital Health Platform.

Affinivax, Inc. (“Affinivax”), a clinical stage biotechnology company with its novel MAPS™ technology platform for vaccines and immunotherapies, today announced the presentation of initial data from a Phase 1/2 clinical trial of its lead vaccine candidate targeting Streptococcus pneumoniae (ASP3772, partnered with Astellas Pharma Inc.)